Education
About Us
Working with TipRanks
Follow Us
Biotest AG (DE:BIO)
HAMBURG:BIO
BIO Stock Chart & Stats
€36.20
€0.40(0.96%)
At close: 4:00 PM EST
€36.20
€0.40(0.96%)
Day’s Range― - ―
52-Week Range€33.00 - €45.60
Previous CloseN/A
Volume121.00
Average Volume (3M)73.00
Market Cap
€1.36B
Enterprise Value€2.18B
Total Cash (Recent Filing)€119.50M
Total Debt (Recent Filing)€597.20M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,785,727
10 Day Avg. Volume62
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Secured Plasma Supply (vertical Integration)Owning plasma collection centers secures raw material supply for immunoglobulins and albumin, reducing reliance on third parties. This durable vertical integration supports production continuity, price negotiation power with buyers, and lowers supply disruption risk over the medium term.
Improved Free Cash FlowA material swing to positive free cash flow and an Operating Cash Flow to Net Income ratio of 2.31 demonstrate stronger cash conversion. Sustained FCF strengthens funding for capex, R&D, deleveraging or shareholder returns and increases resilience to earnings volatility.
Margin RecoveryImproved gross and net margins indicate better unit economics and some pricing or cost control gains in plasma-derived therapies. If sustained, these margins provide room to fund development, absorb input cost swings, and support longer-term profitability despite sector cyclicality.
Bears Say
Inconsistent Revenue TrendsFundamentals show a pronounced negative revenue-growth metric, despite a reported 6.08% year-over-year rise in 2023–24. This mismatch signals inconsistent top-line performance across reporting periods, making capacity planning, investment sizing and long-term forecasting more uncertain.
Eroding Operating MarginsReported declines in EBIT and EBITDA margins point to structural cost pressure or operational inefficiencies in production or SG&A. Persistent margin erosion would weaken cash generation, constrain R&D investment, and reduce the buffer against pricing or raw-material volatility over the medium term.
Elevated Leverage RiskA D/E of ~1.13 and rising total debt reduce financial flexibility and increase interest and refinancing risk. For a biotech with ongoing capex and R&D needs, higher leverage limits strategic optionality and heightens vulnerability if cash flow or margins weaken over the next several quarters.
Biotest News
BIO FAQ
What was Biotest AG’s price range in the past 12 months?
Biotest AG lowest stock price was €33.00 and its highest was €45.60 in the past 12 months.
What is Biotest AG’s market cap?
Biotest AG’s market cap is €1.36B.
When is Biotest AG’s upcoming earnings report date?
Biotest AG’s upcoming earnings report date is Mar 26, 2026 which is in 30 days.
How were Biotest AG’s earnings last quarter?
Currently, no data Available
Is Biotest AG overvalued?
According to Wall Street analysts Biotest AG’s price is currently Overvalued.
Does Biotest AG pay dividends?
Biotest AG pays a Annually dividend of €0.04 which represents an annual dividend yield of N/A. See more information on Biotest AG dividends here
What is Biotest AG’s EPS estimate?
Biotest AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotest AG have?
Biotest AG has 19,785,727 shares outstanding.
What happened to Biotest AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biotest AG?
Currently, no hedge funds are holding shares in DE:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biotest Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.09%
Trailing 12-Months
Company Description
Biotest AG
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Technical Analysis
Eckert & Ziegler Strahlen und Medizintechnik
―
Epigenomics
―
Evotec
―
Medios AG
―
Formycon AG
―